U.S. Hemophilia Treatment Market GRÖSSEN- UND MARKTANTEILSANALYSE - WACHSTUMSTRENDS UND PROGNOSEN (2024 - 2031)
U.S. Hemophilia Treatment Market is Segmented By Product Type (Recombinant Coagulation Factor, Plasma Derived Coagulation Factor, Antifibrinolytic Agents, and Others), By Disease Type (Hemophilia A, Hemophilia B, and Hemophilia C), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies). The report offers the value (in USD billion) for the above-mentioned segments.
Competitive overview of U.S. Hemophilia Treatment Market
Zu den wichtigsten Akteuren, die im US-Hemophilia-Behandlungsmarkt tätig sind, gehören Takeda Pharmaceutical Company Limited. Sanofi Octapharma AG, Swedish Orphan Biovitrum AB, Baxter International Inc., Biogen Inc., Bayer AG, CSL Behring, Ferring B.V., Pfizer, Inc., Kedrion, Novo Nordisk A/S, Grifols S.A., Sangamo Therapeutics, Inc. und Spark Therapeutics, Inc.
U.S. Hemophilia Treatment Market Leaders
- Takeda Pharmaceutical Unternehmen Limited
- Sanofi Octapharma AG
- Schwedisch Orphan Biovitrum AB
- Baxter International Inc.
- Biogen Inc.
U.S. Hemophilia Treatment Market - Competitive Rivalry, 2023
U.S. Hemophilia Treatment Market
(Dominated by major players)
(Highly competitive with lots of players.)